Daily Archives: November 17, 2021

Asciminib is approved for Philadelphia chromosome-positive chronic myeloid leukemia

November 17th, 2021 Blood cancer, Leukemia

Nov 2021: Asciminib (Scemblix, Novartis AG) was given accelerated approval by the Food and Drug Administration for patients with Philadelphia chromosome-positive chronic myeloid leukaemia (Ph+ CML) in chronic phase (CP) who had previously receiv.... Read More

Atezolizumab is approved by FDA as adjuvant treatment for non-small cell lung cancer

November 17th, 2021 Lung cancer

Nov 2021: The Food and Drug Administration has approved atezolizumab (Tecentriq, Genentech, Inc.) for adjuvant treatment in patients with stage II to IIIA non-small cell lung cancer (NSCLC) whose tumours contain PD-L1 expression on less than 1% .... Read More

Pembrolizumab combination is approved by FDA for the first-line treatment of cervical cancer

November 17th, 2021 Cervical cancer

Nov 2021: Pembrolizumab (Keytruda, Merck) in conjunction with chemotherapy, with or without bevacizumab, has been approved by the Food and Drug Administration for patients with persistent, recurrent, or metastatic cervical cancer whose tumours e.... Read More